Angiotensin II promotes the anticoagulant effects of rivaroxaban via angiotensin type 2 receptor signaling in mice

Rivaroxaban is an oral direct factor Xa inhibitor approved for the treatment of stroke and systemic thromboembolism in patients with non-valvular atrial fibrillation. Despite its efficacy, rivaroxaban therapy results in adverse effects and complications, such as bleeding. Angiotensin II (AngII) is i...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Dan, Shao, Junjie, Hu, Ruifeng, Chen, Haimei, Xie, Ping, Liu, Chang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5428434/
https://www.ncbi.nlm.nih.gov/pubmed/28337024
http://dx.doi.org/10.1038/s41598-017-00473-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5428434/
https://www.ncbi.nlm.nih.gov/pubmed/28337024
http://dx.doi.org/10.1038/s41598-017-00473-5

Ejemplares similares